Abstract
A clinical decision report appraising van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46. https://doi.org/10.1016/S1474-4422(17)30378-2
DOI
10.22237/crp/1593562440
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
ROSS B. Subcutaneous immunoglobulin proves to be an effective alternative to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyneuropathy. Clin. Res. Prac. Oct 16 2020;6(2):eP2170. https://doi.org/10.22237/crp/1593562440
Included in
Medical Education Commons, Nervous System Diseases Commons, Neurology Commons, Translational Medical Research Commons
